Tarrytown, New York, United States, November 18, 2026
Regeneron Pharmaceuticals, Inc. has announced that the U.S. Food and Drug Administration (FDA) has approved Livsayis™ (cemdisiran) for the treatment of adults with generalized myasthenia gravis (gMG) who test positive for anti-acetylcholine receptor (AChR) antibodies. The approval marks a significant milestone in the treatment of this chronic autoimmune neurological disease, as Livsayis becomes the first and only approved small interfering RNA (siRNA) therapy for generalized myasthenia gravis. Additionally, it is the only FDA-approved treatment for gMG that can be administered through a subcutaneous injection just four times a year, offering a dosing schedule of once every three months. The approval is supported by positive results from the Phase 3 NIMBLE clinical trial, which demonstrated rapid, meaningful and sustained improvements in disease symptoms and daily functioning.
Livsayis Introduces a New siRNA Approach to gMG Treatment
Livsayis represents an important advancement in the application of RNA interference technology for neurological and autoimmune diseases. The therapy is designed to target complement component 5 (C5), a protein involved in the terminal complement pathway that contributes to disease-related damage in patients with AChR-antibody-positive generalized myasthenia gravis. Cemdisiran works by using small interfering RNA (siRNA) to degrade the messenger RNA responsible for producing C5 protein. By reducing circulating C5 levels, the treatment helps limit terminal complement activation, which plays a significant role in the disease process. Generalized myasthenia gravis is a rare, chronic autoimmune condition characterized by fluctuating muscle weakness and fatigue. It can affect several muscle groups, resulting in difficulties with speaking, chewing, swallowing, breathing, vision and mobility. Severe disease exacerbations can also become life-threatening. The availability of a treatment targeting this biological pathway provides another therapeutic option for eligible adult patients.
Phase 3 NIMBLE Trial Demonstrates Significant Improvements
The FDA approval was based on findings from the Phase 3 NIMBLE clinical trial, a randomized, double-blind, placebo-controlled study evaluating cemdisiran in patients with AChR-antibody-positive gMG. The study demonstrated improvements across important clinical measures, including the Myasthenia Gravis Activities of Daily Living (MG-ADL) score and the Quantitative Myasthenia Gravis (QMG) score. At Week 24, patients receiving Livsayis achieved a 4.5-point improvement in MG-ADL scores, compared with a 2.2-point improvement among patients receiving placebo. This represented a statistically significant placebo-adjusted improvement of 2.3 points (p=0.0005). Furthermore, 76.6% of Livsayis-treated patients achieved at least a three-point improvement in MG-ADL, compared with 44.1% in the placebo group. The QMG assessment also showed encouraging results, with a 4.2-point improvement among Livsayis-treated patients compared with 1.5 points in the placebo group at Week 24. The treatment demonstrated a placebo-adjusted improvement of 2.8 points (p=0.0015). Importantly, clinically meaningful improvements in MG-ADL scores were observed as early as two weeks after treatment initiation. The company also reported that symptom improvements were maintained throughout the 24-week assessment period, without evidence of diminishing efficacy toward the end of the three-month dosing intervals.
Safety Profile and Four-Times-a-Year Administration
One of the key features of Livsayis is its subcutaneous administration every three months, potentially reducing the treatment burden associated with more frequent dosing schedules. However, the therapy carries important safety considerations. Its prescribing information includes a Boxed Warning for serious meningococcal infections, along with warnings concerning other serious infections associated with reduced C5 activity. Patients must complete the required meningococcal vaccinations at least two weeks before starting treatment. Livsayis is available through a restricted Risk Evaluation and Mitigation Strategy (REMS) program to support appropriate risk management. The most common adverse reactions reported in treated patients were injection-site reactions, viral infections and urinary tract infections. Healthcare professionals must evaluate patients carefully and follow the recommended vaccination and safety requirements before initiating therapy.
The approval also represents a major achievement for Regeneron’s neuroscience and genetic medicine development programs. Livsayis is the company’s first approved siRNA therapy and its first approved neurology medicine. Regeneron is responsible for the development, manufacturing and commercialization of cemdisiran under a worldwide licensing agreement with Alnylam Pharmaceuticals, highlighting the collaboration behind the therapy’s development. Regulatory review of Livsayis for gMG is ongoing in the European Union, with a decision anticipated in the second half of 2027. The company also plans regulatory submissions in additional markets, including Japan. Overall, the FDA approval introduces a new RNA-based therapeutic approach for adults living with generalized myasthenia gravis and highlights the growing role of RNA-targeting medicines in the treatment of complex neurological and autoimmune diseases.
Source: Regeneron press release



